Earnings Recaps

Browse reported earnings of the most popular stocks

Aug 14, 2026 Aug 13, 2026 Aug 12, 2026 Aug 11, 2026 Aug 10, 2026 Aug 9, 2026 Aug 8, 2026 Aug 7, 2026 Aug 6, 2026 Aug 5, 2026 Aug 4, 2026 Aug 3, 2026 Aug 2, 2026 Aug 1, 2026 Jul 31, 2026 Jul 30, 2026 Jul 29, 2026 Jul 28, 2026 Jul 27, 2026 Jul 26, 2026 Jul 25, 2026 Jul 24, 2026 Jul 23, 2026 Jul 22, 2026 Jul 21, 2026 Jul 20, 2026 Jul 19, 2026 Jul 18, 2026 Jul 17, 2026 Jul 16, 2026 Jul 12, 2026 Jul 11, 2026 Jul 10, 2026 Jul 9, 2026 Jul 3, 2026 Jul 2, 2026 Jul 1, 2026 Jun 30, 2026 Jun 28, 2026 Jun 27, 2026 Jun 26, 2026 Jun 25, 2026 Jun 24, 2026 Jun 20, 2026 Jun 19, 2026 Jun 18, 2026 Jun 17, 2026 Jun 15, 2026 Jun 14, 2026 Jun 13, 2026 Jun 12, 2026 Jun 11, 2026 Jun 10, 2026 Jun 9, 2026 Jun 6, 2026 Jun 5, 2026 Jun 4, 2026 Jun 3, 2026 Jun 2, 2026 Jun 1, 2026 May 31, 2026 May 30, 2026 May 29, 2026 May 28, 2026 May 27, 2026 May 26, 2026 May 24, 2026 May 23, 2026 May 22, 2026 May 21, 2026 May 20, 2026 May 19, 2026 May 18, 2026 May 17, 2026 May 16, 2026 May 15, 2026 May 14, 2026 May 13, 2026 May 12, 2026 May 11, 2026 May 10, 2026 May 9, 2026 May 8, 2026 May 7, 2026 May 6, 2026 May 5, 2026 May 4, 2026 May 3, 2026 May 2, 2026 May 1, 2026 Apr 30, 2026 Apr 29, 2026 Apr 23, 2026 Apr 22, 2026 Apr 21, 2026 Apr 20, 2026 Apr 18, 2026 Apr 17, 2026 Apr 16, 2026 Apr 15, 2026 Apr 14, 2026 Apr 13, 2026 Apr 10, 2026 Apr 9, 2026 Apr 8, 2026 Apr 7, 2026 Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026 Mar 2, 2026 Feb 28, 2026 Feb 27, 2026 Feb 26, 2026 Feb 25, 2026 Feb 24, 2026 Feb 23, 2026 Feb 21, 2026 Feb 20, 2026 Feb 19, 2026 Feb 18, 2026 Feb 17, 2026 Feb 14, 2026 Feb 13, 2026 Feb 12, 2026 Feb 11, 2026 Feb 10, 2026 Feb 9, 2026 Feb 7, 2026 Feb 6, 2026 Feb 5, 2026 Feb 4, 2026 Feb 3, 2026 Feb 2, 2026 Jan 31, 2026 Jan 30, 2026 Jan 29, 2026 Jan 28, 2026 Jan 27, 2026 Jan 26, 2026 Jan 23, 2026 Jan 22, 2026 Jan 21, 2026 Jan 20, 2026 Jan 17, 2026 Jan 16, 2026 Jan 15, 2026 Jan 14, 2026 Jan 9, 2026 Jan 8, 2026 Jan 7, 2026 Jan 6, 2026 Dec 19, 2025 Dec 18, 2025 Dec 17, 2025 Dec 12, 2025 Dec 11, 2025 Dec 10, 2025 Dec 9, 2025 Dec 6, 2025 Dec 5, 2025 Dec 4, 2025 Dec 3, 2025
49 companies Today

Apple Inc.

AAPL Q3 2026
Reported: 2026-08-02

Apple’s shares dropped 8.7% following earnings as investors were likely disappointed by an implied cautious outlook and potential margin pressure despite reported revenue records across multiple categories and geographies.

Key takeaways
  • Reported revenue of $109.4 billion, up 16% year-over-year, setting a June quarter record.
  • iPhone revenue grew 22% to $54.3 billion, with gains in every geographic segment and share gains noted.
  • Mac revenue rose 29% to $10.4 billion, driven by strong demand for MacBook Pro and MacBook Neo despite supply constraints.
  • Services set a June quarter record at $30.7 billion, contributing to overall growth.
  • Wearables, home, and accessories revenue increased 6% to $7.9 billion, including a record quarter for Apple Watch upgraders.

AbbVie Inc.

ABBV Q2 2026
Reported: 2026-08-02

AbbVie's shares declined 2.5% following Q2 earnings despite beatings in revenue and EPS, reflecting investor caution likely tied to ongoing biosimilar erosion in HUMIRA and mixed segment performance that tempered enthusiasm.

Key takeaways
  • Adjusted EPS came in at $3.65, $0.06 above guidance midpoint, with total net revenues nearly $17 billion, beating expectations by $300 million.
  • Immunology sales grew 14.6% operationally to $8.8 billion, driven by SKYRIZI’s 24% growth and RINVOQ’s 23.7% growth; however, HUMIRA sales declined 36.1% due to biosimilar competition.
  • Pipeline progress included FDA approval of Decnapaz and multiple European approvals (QLIPTA, Epkinly, Bowie, RINVOQ in derm conditions) with raised peak sales expectations for new indications.
  • AbbVie announced acquisition of Apogee Therapeutics to deepen immunology pipeline, signaling focus on sustaining long-term growth.
  • Despite revenue and earnings beats, the stock’s negative reaction suggests investor concerns around biosimilar impact and potentially cautious outlook on margin pressures or growth sustainability.

Alnylam Pharmaceuticals, Inc.

ALNY Q2 2026
Reported: 2026-08-02

Alnylam’s shares plunged 28.3% post-earnings as the company lowered its 2026 revenue guidance, disappointing investors with signs of demand normalization and a cautious outlook amid early second-line demand tapering.

Key takeaways
  • 2026 revenue guidance was reduced to reflect normalized demand following an initial surge driven by pent-up second-line patient starts.
  • AMVUTTRA revenues surpassed $1 billion in Q2, marking an annualized run rate above $4 billion, but growth is shifting heavily towards first-line new patient starts (~80% of category growth).
  • The company cited competitive headwinds, including the failure of a rival’s cardiovascular outcomes trial, but maintained confidence in its Phase III TRITON-CM study with potential study adaptations under consideration.
  • Geographic expansion efforts continue, notably a new collaboration targeting the China and Macau markets, contingent on regulatory approval.
  • Investment in AI-driven discovery and disease identification partnerships underscores a longer-term innovation strategy despite short-term growth challenges.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...